Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.27 | N/A | +122.81% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.27 | N/A | +122.81% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to strategic growth. They emphasized the importance of partnerships in driving future success.
We are pleased with our EPS performance this quarter.
Our focus remains on strategic partnerships and innovation.
Ligand Pharmaceuticals reported a strong EPS performance, significantly exceeding expectations, which contributed to a modest stock increase of 0.57%. However, the lack of revenue data and forward guidance leaves some uncertainty about the company's future performance. Investors may be encouraged by the positive EPS surprise but will likely look for more information in future updates.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PUBLIC STORAGE REIT
Feb 24, 2025